trending Market Intelligence /marketintelligence/en/news-insights/trending/V-IIEuqWyGkdmxUKcVBb1w2 content esgSubNav
In This List

Oasmia Pharmaceutical to move veterinary assets to US

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


Oasmia Pharmaceutical to move veterinary assets to US

Oasmia Pharmaceutical AB (publ) intends to move all of its veterinary assets to the U.S. for further development and commercialization efforts.

The assets include Paccal Vet and Doxophos Vet, the company's products within the field of chemotherapy for companion animals, which they own worldwide distribution rights to, except for Japan.

Oasmia aims to transition the products on a broader scale to a larger number of veterinary clinics. In line with this, Oasmia will transfer all the rights for the two key products to its subsidiary in the U.S to further facilitate strategic development and collaborations.

The company believes it can garner significant market share of the expanding U.S. veterinary industry by reducing the side effects and making its two key products more appealing to general practitioners.

Oasmia expects to implement the strategic changes during 2017.